Technology ID

A New Mouse Monoclonal Antibody Against Human Microphthalmia Transcription Factor (MITF)

Lead Inventor
Arnheiter, Heinz (National Institute of Neurological Disorders and Stroke)
Liu, Wen Fang (National Institute of Neurological Disorders and Stroke)
Murakami, Hideki (Aichi Cancer Center Research Institute)
Research Materials
Therapeutic Areas
Development Status
The technology is ready for the market.
Lead IC
Micropthalmia Transcription Factor (MITF) plays an important role in melanocyte development and melanoma growth. MITF is important for embryonic development, regulating the generation of pigment cells and formation of melanomas and other tumors. MITF is made in various isoforms that may play unique roles for different organs during different developmental periods. Additionally, tissue MITF levels can serve as a molecular marker for the diagnosis of metastatic melanoma and therapeutic response.

This technology involves the generation of several novel mouse monoclonal antibodies against a sub-domain of an MITF fragment that is cleaved during cell death. Importantly, these antibodies cross-react with human MITF. The antibody was raised by immunizing mice that are incapable of producing the MITF sub-domain used as the antigen. Three (3) different "clones" of these antibodies are currently available and their corresponding hybridoma names are 6A5 (IgG1), 1D2 (IgG2a) and 3D1 (IgG2a).
Commercial Applications
  • Novel mouse monoclonal antibodies specific to a domain of MITF as research material
  • Novel mouse monoclonal antibodies that cross react with human MITF
Licensing Contact:
Specialist (ALS), Admin. Licensing